2024 Hematology Highlights (Attendee Information)
This site is intended for registered participants of 2024 Hematology Highlights: A Post-ASH Review.
Welcome! Thank you for joining us.
The University of Nebraska Medical Center has sponsored this regional conference for the last 17 years. This year's conference is designed to update the target audience on new treatments and management of acute and chronic leukemia, acute myeloid leukemia, multiple myeloma, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, bleeding disorders, as well as myths and sciences behind dietary recommendations for patients with cancer as presented during the 2023 annual meeting of the American Society of Hematology. Presentations will be delivered by key leaders while allowing the opportunity for participants to be involved in the interactive question/answer sessions.
Conference Objectives
At the conclusion of this activity, the participant should be better able to:
- Articulate the mechanism of action surrounding new therapies and the process for appropriate patient selection when caring for those with hematologic malignancies and non-malignant hematologic disorders.
- Analyze emerging data regarding new clinical, genetic, and molecular prognostic factors, and how to use them for improved precision approaches for the treatment of hematologic malignancies.
- Discuss recent clinical trials that demonstrate a reduction of treatment intensity involving therapies such as a combination of pharmacologic strategies when caring for those with hematologic malignancies.
- Summarize the impact of the evidence-based findings from the 2023 ASH meeting surrounding the management of hematologic malignancies and other disorders of thrombosis and hemostasis in clinical practice.
- Recognize how to safely initiate and use BCL2 inhibitors and interpret the current recommendations for antimicrobial prophylaxis for patients with AML.
- Determine common nutritional and dietary misconceptions for patients diagnosed with cancer, including hematologic malignancies, while utilizing current evidence-based recommendations for diet and nutrition in patients with hematologic malignancies.
- Describe the roles and responsibilities of the health care team when managing hematologic malignancies from the assessment, evaluation, and management perspectives.
General Information
Saturday, Feb. 3, 2024
Read the UNMC CCE Disclosure Declaration Policy
Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
FACULTY
The following have nothing to disclose:
- Allison M. Graner, PharmD, BCOP
The following have disclosed relevant financial relationships:
- John N. Allan, MD
Consultant/Honoraria: AbbVie Inc.; Adaptive Biotechnologies; ADC Therapeutics America, Inc.; AstraZeneca; BeiGene USA, Inc.; Ipsen Biopharmaceuticals, Inc.; Genentech USA, Inc.; Janssen Pharmaceuticals, Inc.; Lava Therapeutics N.V.; Eli Lilly & Co.; Pharmacyclics, An AbbVie Company; TG Therapeutics, Inc.
Research: BeiGene USA, Inc.; Genentech USA, Inc.; Janssen Pharmaceuticals - Jacqueline S. Garcia, MD
Scientific Advisory Board: AbbVie Inc.;Genentech USA, Inc.; Servier U.S.; Bristol Myers Squibb
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: TBD - I will present the ASH abstracts and indicate off-label investigational drugs with each presentation highlight
- Neha Mehta-Shah, MD, MSCI
Advisory Board: AstraZeneca; C4 Therapeutics, Inc.; Daiichi Sankyo, Inc.; Genentech USA, Inc.; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Pfizer, Inc.
Research Funding: AstraZeneca; Bristol Myers Squibb; C4 Therapeutics, Inc.; Celgene Corporation, A Bristol Myers Squibb Company; Corvus Pharmaceuticals; Daiichi Sankyo, Inc.; Dizal Pharmaceuticals; Genentech USA, Inc.; Incyte Corporation; Innate Pharma, Inc. - Alex B. Nester, MD
Research Grant: AstraZeneca
Travel Support: GT Medical Technologies, Inc. - Keith W. Pratz, MD
Advisory Board: AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca; Celgene Corporation, A Bristol Myers Squibb Company; Jazz Pharmaceuticals, Inc.
Research Funding: AbbVie Inc.; Astellas Pharma Inc. - Ashley E. Rosko, MD
Consultant: Curio Science, a Vaniam Group company; Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)
Research Support: Sanofi
Speaker: American Society for Transplantation and Cellular Therapy (ASTCT)
Travel Support: American Society of Hematology (ASH) - Michelle Spink, RD, LMNT
Research Grant: AstraZeneca
Travel Support: GT Medical Technologies, Inc. - Amer M. Zeidan, MBBS, MHS
Consultant/Honoraria: AbbVie Inc.; Agios Pharmaceuticals, Inc.; ALX Oncology Inc.; Amgen USA; Aprea Therapeutics; Astellas Pharma Inc.; BeyondSpring Inc.; BioCryst Pharmaceuticals, Inc.; Bristol Myers Squibb; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc; Cardinal Health; Celgene Corporation, A Bristol Myers Squibb Company; CHIESI USA, Inc.; Daiichi Sankyo, Inc.; Ipsen Biopharmaceuticals, Inc.; Foran Healthcare; Genentech USA, Inc.; Geron; Gilead Sciences, Inc.; Incyte Corporation; Ionis Pharmaceuticals; Janssen Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Kura Oncology, Inc.; Mendus; Merck & Co., Inc.; Notable; Novartis, Inc.; Orum Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc; Pfizer, Inc.; Seagen Inc.; Servier U.S.; Syndax Pharmaceuticals; Syros Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals USA, Inc; Tyme Technologies, Inc.
Clinical Trial Committee: AbbVie Inc.; ALX Oncology Inc.; BioCryst Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation, A Bristol Myers Squibb Company; Geron; Gilead Sciences, Inc.; Kura Oncology, Inc.; Novartis, Inc.; Syros Pharmaceuticals, Inc.
Research Funding: AbbVie Inc.; ADC Therapeutics SA; Amgen USA; Aprea Therapeutics; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc; Celgene Corporation, A Bristol Myers Squibb Company; Geron; Incyte Corporation; Medimmune; Novartis, Inc. ;Otsuka America Pharmaceutical, Inc; Pfizer, Inc.; Shattuck Labs, Inc.; Takeda Pharmaceuticals USA, Inc
Travel Support: Cardiff Oncology, Inc; Novartis, Inc.; Pfizer, Inc.
PLANNING COMMITTEE
The following have disclosed relevant financial relationships:
- Vijaya Raj Bhatt, MBBS, MS*
Consultant, Safety Monitoring Committee: Imugene Limited; Protagonist Therapeutics Inc.
Research Funding: AbbVie Inc.; Actinium Pharmaceuticals, Inc.; Incyte Corporation; Jazz Pharmaceuticals, Inc.; MEI Pharma, Inc.; National Marrow Donor Program; Pfizer, Inc.; Sanofi
Drug Support for a trial: Chimerix - Christopher R. D’Angelo, MD*
Advisory Board: Bristol Myers Squibb; Ono Pharma USA, Inc.; Seagen Inc.Consultant: AbbVie Inc.
Research: AbbVie Inc.; BeiGene USA, Inc.; Bristol Myers Squibb; Fate Therapeutics; Ono Pharma USA, Inc. - Jared Matya, PharmD, BCOP
Advisory Board: AstraZeneca; Genmab A/S
Speaker's Bureau: BTG International Ltd.
- Valeta Creason-Wahl, HMCC
- Julie Huglin
- Heidi Keeler, PhD, MSN/MBA, RN
- Renee Paulin, MSN, RN, CWOCN
- Brenda Ram, CMP, CHCP
*Faculty and planning committee member
The following materials (in PDF) are available for download until Feb. 23, 2024. No part of these materials may be reproduced without permission.
- Myelodysplastic Syndromes: 2023 Updates
Amer M. Zeidan, MBBS, MHS - Advances in Acute Leukemia
Keith W. Pratz, MD - Myeloproliferative Neoplasms: What’s New in 2023?
Jacqueline S. Garcia, MD - New Chemotherapy and Antimicrobial Prophylaxis in Acute Myeloid Leukemia: Practical Tips
Allison M. Graner, PharmD, BCOP - Multiple Myeloma Updates for 2024
Ashley E. Rosko, MD - Chronic Lymphocytic Leukemia Advances from ASH 2023
John N. Allan, MD - Lymphoma Highlights from ASH 2023
Neha Mehta-Shah, MD, MSCI - Myths and Science Behind Diet Recommendations for Patients with Cancer
Michelle Spink, RD, LMNT - Advances in Bleeding Disorders
Alex B. Nester, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must:
- Check in at the registration desk and attend the live activity.
- Complete the online evaluation via the UNMC MyCCE portal.
- On your dashboard, click Evaluate an Activity.
- Enter Activity Code 59072.
You have until Feb. 23, 2024, to claim credit for this activity. You will need to complete the evaluation and attest to the time you spent participating in the activity. Your certificate will be saved in your UNMC MyCCE account under Certificates & Transcripts.
Need help managing your MyCCE account? Find answers to commonly asked questions about signing in to the portal, completing the online evaluation, retrieving your certificate, and more. Go to Manage MyCCE Account
Conference Directors
Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, UNMC
Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, UNMC
Exhibitors
ADC Therapeutics America, Inc.
AbbVie Inc.
Alexion Pharmaceuticals Inc.
Amgen USA
Astellas Pharma Inc.
AstraZeneca
BeiGene USA, Inc.
Biomarin Pharmaceuticals
Blueprint Medicines Corporation
Bristol Myers Squibb
CSL Behring, LLC
Daiichi Sankyo, Inc.
EMD Serono Inc.
Eli Lilly & Co.
Genentech USA, Inc.
Genmab
Incyte Corporation
Janssen Pharmaceuticals
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Merck & Company
Nebraska Medicine
Novartis, Inc.
Omeros Corporation
Pfizer, Inc.
Pharmacyclics, An AbbVie Company
PharmaEssentia USA Corporation
Rigel Pharmaceuticals Inc.
Sanofi
Seagen Inc.
Servier U.S.
Sobi, Inc.
Stemline Therapeutics, Inc.
Taiho Oncology Inc.
Takeda Pharmaceuticals USA, Inc.
Questions?
Director, Educational Programs
UNMC Center for Continuing Education
